FDA approval for Pfizer Covid vaccine could come Monday, report says
Empty vials of the Pfizer COVID-19 vaccine are seen at a first come first serve drive-thru vaccination site operated by the Lake County Health Department on January 28, 2021 in Groveland, Florida.
Paul Hennessy | NurPhoto | Getty Images
The review process could move past that date, The Times said, as paperwork and negotiations with the company continue.
The move would make it the first vaccine to go from emergency use authorization to full FDA approval.
The FDA declined to comment on the Times report to CNBC.
White House chief medical advisor Dr. Anthony Fauci told the Associated Press Aug. 8 that he hoped vaccines would start receiving full approval “within the month of August,” adding that full approval would lead more companies and schools to mandate vaccines.
Full approval from the FDA could also help convince individuals hesitant about getting vaccinated until the shot was fully signed off on.
More than 203 million doses of Pfizer and BioNTech’s vaccine have been administered nationwide, fully immunizing over 91 million people in the U.S., according to the CDC.
Pfizer and BioNTech initially began the process of applying for their biologics license for the two-dose vaccine in May after receiving emergency use authorization from the FDA last December. The FDA sets a six-month target for approving high-priority drugs.
The companies announced on Aug. 16 that they began the approval process for a booster dose after submitting clinical trial data to the FDA.
If formally authorized, Pfizer and BioNTech’s vaccine would remain available on the market after the pandemic ends, and the companies would also be able to advertise the vaccine directly to consumers. Pharmaceutical manufacturers with an EUA are prohibited from promoting their vaccines, CNBC previously reported.
Top health officials from agencies including the Centers for Disease Control and Prevention, White House and FDA said in a statement Wednesday that the effectiveness of mRNA vaccines declines over time, especially for those with compromised immune systems or for anyone inoculated early in the vaccine rollout.
Charles Schwab is Trading at All-Time Highs, is it Still a Buy? By StockNews
© Reuters. Charles Schwab is Trading at All-Time Highs, is it Still a Buy? Impressive third-quarter earnings and increased retail…
Verizon profit tops expectations, broadband continues to see growth
Verizon Communications Inc. topped earnings estimates for its latest quarter but came up a bit short on revenue as the…